Dr Markku Jalkanen, CEO of Faron, said: "This is another piece of good news for Faron during a highly successful year and we are now focused on demonstrating that our wholly-owned lead product, Traumakine, has applicability in RAAA
patients as well as in the ARDS indication.
All patients presenting to the emergency department with a diagnosis of RAAA (as defined by the presence of retroperitoneal or intraperitoneal blood or both) were included in the study.
Retrospective data were obtained on all patients with a diagnosis of RAAA using the Australian and New Zealand Intensive Care Society database as recorded using STATIC software and the patient's medical records.
Epidemiological studies on abdominal aortic aneurysms have shown an increasing incidence of RAAA (6-8).
Several factors were found to be associated with an increased mortality following RAAA.
This may imply that presence of COPD in older patients presenting with RAAA may be a factor that increases mortality.
The impact of delay to surgery on survival in patients with RAAA was evaluated in a retrospective study by Salhab et al (18).
The decreased mortality associated with RAAA when surgery is performed by a vascular surgeon is consistent with published data from Massachusetts that reviewed RAAA in five community hospitals over a 12-year period.
Such data could further clarify the role of COPD in the overall outcome of patients with RAAA.